Regenacy Pharmaceuticals
PrivateLast Round
Series B
Aug 24, 2022
Total Funding Raised
$39.3M
Company Overview
Regenacy Pharmaceuticals operates in Healthcare & Life Sciences and is based in Waltham, Massachusetts. Its latest recorded funding round was a Series B round in August 2022.
Regenacy Pharmaceuticals is a biopharmaceutical company that develops innovative therapeutic drugs using a novel, disease-modifying approach to treat peripheral neuropathy and related conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Regenacy Pharmaceuticals Comparables
Compare Regenacy Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Augustine Therapeutics | 91% | |
| Novaremed AG | 83% | |
| WinSanTor | 81% |
For institutional investors. Book with your work email.
Regenacy Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 24, 2022 | ||||
| Series A | Mar 25, 2020 |
For institutional investors. Book with your work email.
Regenacy Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Taiwania Capital | Series B, Series A |
| Bencao Capital | Series A, Series B |
| Yonjin Capital | Series A |
| Viva Biotech | Series A |
| TA YA VENTURE HOLDINGS LIMITED | Series A |
| Yonjin Capital | Series A |
| Cobro Ventures | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 24, 2022
$9.3M round led by Cobro Ventures.
For institutional investors. Book with your work email.
Regenacy Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Regenacy Pharmaceuticals's valuation, stock price, and market status.
Is Regenacy Pharmaceuticals a public or private company?
Regenacy Pharmaceuticals is a private company.
What is the current stock price of Regenacy Pharmaceuticals?
Regenacy Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Regenacy Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Regenacy Pharmaceuticals worth (valuation)?
Valuation information for Regenacy Pharmaceuticals is not publicly available.
Can I buy Regenacy Pharmaceuticals stock?
Regenacy Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Regenacy Pharmaceuticals's last funding round?
Regenacy Pharmaceuticals's most recent funding round was Series B on August 24, 2022.
Who are the main investors in Regenacy Pharmaceuticals?
Key investors in Regenacy Pharmaceuticals include Taiwania Capital, Cobro Ventures.
Will Regenacy Pharmaceuticals IPO soon?
No public IPO plans have been announced for Regenacy Pharmaceuticals.
How can I track Regenacy Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Regenacy Pharmaceuticals's shares on secondary markets.